These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23441717)

  • 1. Acid burn or cytokine sizzle in the pathogenesis of heartburn?
    Huo X; Souza RF
    J Gastroenterol Hepatol; 2013 Mar; 28(3):385-7. PubMed ID: 23441717
    [No Abstract]   [Full Text] [Related]  

  • 2. Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
    Miwa H; Takubo K; Shimatani T; Furuta T; Oshima T; Tanaka J; Aida J; Ito M; Kurosawa S; Joh T; Wada T; Habu Y; Watanabe Y; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2013 Mar; 28(3):479-87. PubMed ID: 22989221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.
    Dunbar KB; Agoston AT; Odze RD; Huo X; Pham TH; Cipher DJ; Castell DO; Genta RM; Souza RF; Spechler SJ
    JAMA; 2016 May; 315(19):2104-12. PubMed ID: 27187303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
    Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
    Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
    Kindt S; Imschoot J; Tack J
    Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term maintenance therapy with rabeprazole for reflux esophagitis.
    Filik L
    Intern Med; 2011; 50(11):1267; author reply 1269. PubMed ID: 21776623
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
    Fujimoto K; Hongo M;
    Intern Med; 2011; 50(3):179-88. PubMed ID: 21297318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 9. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    Pace F; Coudsy B; DeLemos B; Sun Y; Xiang J; LoCoco J; Casalini S; Li H; Pelosini I; Scarpignato C
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):845-51. PubMed ID: 21900784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M; Miwa H; Kusano M;
    J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proton pump inhibitors may cause squamous epithelial masking of intramucosal carcinoma in Barrett's esophagus.
    Tanaka K; Toyoda H; Kadowaki S; Hamada Y; Kosaka R; Yamanaka M; Imoto I
    Endoscopy; 2007 Feb; 39 Suppl 1():E105-6. PubMed ID: 17440852
    [No Abstract]   [Full Text] [Related]  

  • 12. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
    Pallotta S; Pace F; Marelli S
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):509-22. PubMed ID: 19072398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease.
    Xirouchakis E; Kamberoglou D; Kalos D; Zambeli E; Doulgeroglou V; Tzias V
    Dig Dis Sci; 2009 Feb; 54(2):328-32. PubMed ID: 18600453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
    Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
    Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
    Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
    World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turning the Pathogenesis of Acute Peptic Esophagitis Inside Out.
    Kahrilas PJ
    JAMA; 2016 May; 315(19):2077-8. PubMed ID: 27187299
    [No Abstract]   [Full Text] [Related]  

  • 18. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GERD for the nongastroenterologist: successful evaluation, management, and lifestyle-based symptom control.
    Stein E; Sloan J; Sonu I; Kathpalia P; Jodorkovsky D
    Ann N Y Acad Sci; 2020 Dec; 1482(1):106-112. PubMed ID: 32944973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.